WASHINGTON — The Food and Drug Administration’s top compounding staffer, Julie Dohm, is leaving the agency effective March 29.

Since 2016, Dohm has steered the FDA through the contentious implementation of the compounding law passed by Congress in the wake of a 2012 meningitis outbreak that killed 64. During Dohm’s tenure, FDA released nearly two dozen far-reaching policies, conducted more than 400 inspections of compounders, and took a number of compounding pharmacies to court for alleged violations of the law.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy